Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phathom posts record revenue and narrows losses, but profitability remains just out of reach.

What the company is saying

Phathom Pharmaceuticals, Inc. is emphasizing record Q2 2026 net revenues of $74.3 million, highlighting an 88% year-over-year increase and a 27% sequential rise. The company frames its narrative around strong prescription growth for VOQUEZNA, reporting approximately 325,000 prescriptions filled in the quarter and a cumulative 1.7 million as of July 17, 2026. Management, led by CEO Steven Basta and CFO Sanjeev Narula, stresses operational discipline, citing a 33% reduction in operating expenses and a near-breakeven non-GAAP adjusted net loss of $0.1 million. The update foregrounds progress in clinical development, with completed Phase 2 enrollment in EoE and plans for a Phase 3 trial in NERD, but provides only expected timelines rather than concrete milestones. The tone is confident but measured, with most claims substantiated by disclosed data and forward-looking statements limited to standard guidance and pipeline updates. International sales, product-level revenue details, and new financing activities are omitted, keeping the focus on U.S. performance and operational execution.

What the data suggests

The disclosed numbers show a company in rapid operational improvement. Net revenues for Q2 2026 reached $74.3 million, up 88% from Q2 2025 and 27% from Q1 2026, driven by 325,000 VOQUEZNA prescriptions in the quarter. Covered prescriptions accounted for 64% of the total, with a 79% year-over-year increase. Operating expenses fell to $63.1 million, a 33% reduction from Q2 2025, with both R&D and SG&A costs declining. The net loss narrowed sharply to $17.6 million from $75.8 million a year earlier, and the non-GAAP adjusted net loss was nearly breakeven at $0.1 million. Cash and cash equivalents rose by $1.6 million to $182.5 million, indicating improved cash generation. Updated 2026 revenue guidance was lowered to $310–325 million from $320–345 million, and non-GAAP operating expense guidance tightened to $235–245 million. The company maintains a gross-to-net discount guidance of 55–59% and expects gross margins of approximately 80%. Disclosures are comprehensive for U.S. operations but lack detail on international sales and product-level revenue.

Analysis

The announcement presents a positive tone, supported by strong realised growth in revenues, prescription volumes, and a significant reduction in net loss. The majority of key claims are realised and substantiated by numerical evidence, including net revenues, operating expenses, and prescription data. Forward-looking statements are limited to clinical trial milestones and updated guidance, which are standard for the sector and not exaggerated relative to the evidence. The company discloses both revenue and net loss figures, but as profitability is not yet achieved (net loss remains, though much reduced), the true_signal cannot exceed weak_positive. There is no evidence of narrative inflation or overstatement; language is proportionate to results, and no large capital outlay is paired with only long-dated, uncertain returns.

Risk flags

• ●Profitability remains unproven, with a Q2 2026 net loss of $17.6 million and only a near-breakeven non-GAAP result. The company projects operating profitability excluding stock-based compensation, but actual GAAP profitability is not yet demonstrated, which matters for long-term sustainability.
• ●Updated full-year 2026 revenue guidance was lowered to $310–325 million from $320–345 million. This reduction signals either slower-than-expected growth or increased uncertainty in revenue realization, raising questions about the pace of prescription uptake or market dynamics.
• ●Forward-looking clinical milestones, including Phase 3 trial enrollment and Phase 2 topline results, are scheduled for late 2026. Delays or negative outcomes in these trials could materially impact future growth prospects and the potential for label expansion.
• ●Disclosures omit international sales figures and product-level revenue breakdowns, limiting visibility into geographic diversification and revenue concentration risks. This lack of granularity could obscure underlying weaknesses or dependencies in the business model.

Bottom line

Phathom's Q2 2026 update shows strong revenue growth and sharply reduced losses, with prescription volumes for VOQUEZNA driving the top line. While operational improvements are clear, the company is not yet profitable on a GAAP basis, and guidance for full-year revenue has been trimmed. Clinical pipeline progress is on schedule, but any commercial impact from new indications is at least several quarters away. The narrative is credible, supported by detailed financials and prescription data, but missing information on international sales and product-level revenues leaves some blind spots. Investors should focus on whether Phathom can achieve and sustain true profitability, not just adjusted metrics, and on the outcomes of late-2026 clinical milestones. The most important takeaway is that while momentum is positive, the investment case still hinges on near-term execution and delivery of both financial and clinical targets.

Announcement summary

(NASDAQ:PHAT) Phathom Pharmaceuticals, Inc. reported record Q2 2026 net revenues of $74.3 million, an increase of 88% versus Q2 2025 and 27% versus Q1 2026. The company filled approximately 325,000 total VOQUEZNA prescriptions during the second quarter, with about 209,000 covered prescriptions representing 64% of the total. Q2 2026 operating expenses were $63.1 million, reduced by 33% compared to Q2 2025, and included a non-cash stock-based compensation charge of $6.7 million. Net loss for Q2 2026 was $17.6 million, compared to $75.8 million for Q2 2025, while non-GAAP adjusted net loss was $0.1 million. As of June 30, 2026, cash and cash equivalents were $182.5 million, an increase of $1.6 million from the previous quarter. The company updated its full-year 2026 net revenue guidance to $310–325 million and non-GAAP operating expenses to $235–245 million, and continues to expect to achieve operating profitability for the remainder of 2026 and for the full year, excluding stock-based compensation.

Disagree with this article?